Xlife Sciences AG Delivers Breakthrough in Early Alzheimer’s Detection, Unlocking Major Market Opportunity

This press release is provided in English and German.

Xlife Sciences AG Delivers Breakthrough in Early Alzheimer’s Detection, Unlocking Major Market Opportunity

ZURICH, Switzerland, December 01, 2025 / Biotech Newswire / -- Xlife Sciences AG (SIX: XLS), together with saniva diagnostics GmbH, today announced a landmark achievement: NeuroMex is the world’s first certified and clinically validated medical device for early detection of Alzheimer’s disease based on the recording of motor responsiveness. It has now successfully completed pivotal clinical trials following FDA (513g) and MDR (CE) certification.

NeuroMex delivers 83.5% accuracy in identifying early-stage Alzheimer’s without traditional cognitive tests, enabling rapid, scalable preventive screening. With the device now entering the partnering phase, it is poised to become a standard component of annual health examinations, opening significant revenue streams and strategic partnership opportunities in healthcare and pharmaceuticals.

"NeuroMex transforms early detection, allowing timely interventions and optimized resource use in healthcare," said Jenny Nisser, Managing Director of saniva diagnostics GmbH.
Oliver R. Baumann, CEO of Xlife Sciences AG added that "this positions Xlife Sciences at the forefront of a multi-billion-dollar market for neurodegenerative diagnostics and preventative care."

By combining breakthrough science, regulatory approval, and clinical validation, Xlife Sciences is uniquely positioned to drive adoption, accelerate partnerships, and deliver meaningful impact for patients, healthcare systems, and investors.

Link to the press release

Semantical keywords: Alzheimer Disease, Equipment and Supplies, Delivery of Health Care, Xlife Sciences AG, saniva diagnostics GmbH, NeuroMex, early Alzheimer’s detection, medical device, motor responsiveness, pivotal clinical trials, FDA 513g, CE certification, early-stage Alzheimer’s, preventive screening, partnering phase, healthcare, pharmaceuticals, Jenny Nisser, Oliver R. Baumann, neurodegenerative diagnostics, preventative care

About Xlife Sciences AG (XLS SW)
Xlife Sciences is a Swiss company focused as incubator and accelerator on the value development and commercialization of promising research projects from universities and other research institutions in the life sciences sector, with the aim of providing solutions for high unmet medical needs and a better quality of life. The goal is to bridge research and development to healthcare markets. Xlife Sciences takes carefully selected projects in the four areas of technological platforms, biotechnology/ therapies, medical technology, and artificial intelligence/digital health to the next stage of development and participates in their subsequent performance.

About saniva diagnostics GmbH
saniva diagnostics GmbH is a German medical technology company founded in 2019 in the field of diagnostics and based in Erfurt (Germany). As a spin-off from Jena University Hospital, the company develops and holds the patent for a motor-based testing instrument for early detection of neurodegenerative diseases.

Disclaimer
Some of the information contained in this media release contains forward-looking statements. Readers are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, and that actual results may differ materially from those in the forward-looking statements as a result of various factors. Xlife Sciences undertakes no obligation to publicly update or revise any forward-looking statements.

Contact

Xlife Sciences AG
Dr. Dennis Fink
dennis.fink@xlifesciences.ch 

Source: Biotech Newswire